'Correct' CF Phase II Answer: Vertex Steps to Head of Class?
Vertex Pharmaceuticals Inc.'s approach to cystic fibrosis (CF) pairing the approved therapy Kalydeco (ivacaftor) as a "potentiator" with another compound, VX-661, as a "corrector" gained market-pleasing, top-line, Phase II proof that sent the stock on a skyward ride.
Shares of Cambridge, Mass.-based Vertex (NASDAQ:VRTX) closed Friday at $85.60, up $32.73, or 61.9 percent, after trading as high as $85.90.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter